In other models, anti-CTLA4 antibody treatment has been reported to enhance the T-cell mediated tumour rejection of colon carcinoma [56], melanoma [57], prostate cancer [58] in mouse models as well as in human cancer patients [59], although treatment induced autoimmunity can occur [55]. Here, CTLA4 is linked to neoplasm.